Tekla Life Sciences Investors (HQL)
USD 13.34
(-3.82%)
USD 13.34
(-3.82%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -0.74 | - | -0.62 | - |
| Net Income | 22.35 Million | -104.6 Thousand | 64.53 Thousand | 123.05 Thousand | -70.47 Thousand | 28.66 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | -22.35 Million | 104.6 Thousand | -64.53 Thousand | -123.05 Thousand | 70.47 Thousand | -28.66 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 445.00 | 990.00 | - | 1.12 Million | 41.00 | - |
| Cash at end of period | 477.00 | 445.00 | -0.74 | 1.12 Million | 1.12 Million | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 32.00 | -545.00 | -0.74 | - | 1.12 Million | - |
| Free Cash Flow | - | - | -0.74 | - | -0.62 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | -11.45 Million | 22.35 Million | 16.9 Thousand | 16.9 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | - | - | 11.45 Million | -22.35 Million | -16.9 Thousand | -16.9 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | 822.00 | 445.00 | 445.00 | - |
| Cash at end of period | - | - | 477.00 | 477.00 | 822.00 | -0.48 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | -345.00 | 32.00 | 377.00 | -0.48 |
| Free Cash Flow | - | - | - | - | -0.48 | -0.48 |
SOFTSOL
4DS
NODK
ALTPC
002370
0M0Q